United Therapeutics Corporation Statistics
Share Statistics
United Therapeutics Corporation has 44.64M shares outstanding. The number of shares has increased by -5.32% in one year.
| Shares Outstanding | 44.64M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 43.82M |
| Failed to Deliver (FTD) Shares | 247 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 2.30M, so 5.16% of the outstanding shares have been sold short.
| Short Interest | 2.30M |
| Short % of Shares Out | 5.16% |
| Short % of Float | 5.25% |
| Short Ratio (days to cover) | 7.51 |
Valuation Ratios
The PE ratio is 10.45 and the forward PE ratio is 14.37. United Therapeutics Corporation's PEG ratio is 0.15.
| PE Ratio | 10.45 |
| Forward PE | 14.37 |
| PS Ratio | 4.42 |
| Forward PS | 5.3 |
| PB Ratio | 1.72 |
| P/FCF Ratio | 13.77 |
| PEG Ratio | 0.15 |
Enterprise Valuation
United Therapeutics Corporation has an Enterprise Value (EV) of 9.78B.
| EV / Earnings | 9.93 |
| EV / Sales | 4.2 |
| EV / EBITDA | 7.05 |
| EV / EBIT | 8.26 |
| EV / FCF | 13.09 |
Financial Position
The company has a current ratio of 4.41, with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.41 |
| Quick Ratio | 4.28 |
| Debt / Equity | 0.12 |
| Total Debt / Capitalization | 10.47 |
| Cash Flow / Debt | 1.4 |
| Interest Coverage | 19.98 |
Financial Efficiency
Return on equity (ROE) is 0.16% and return on capital (ROIC) is 13.7%.
| Return on Equity (ROE) | 0.16% |
| Return on Assets (ROA) | 0.14% |
| Return on Capital (ROIC) | 13.7% |
| Revenue Per Employee | 1.99M |
| Profits Per Employee | 843.15K |
| Employee Count | 1.17K |
| Asset Turnover | 0.32 |
| Inventory Turnover | 2.3 |
Taxes
| Income Tax | 289.50M |
| Effective Tax Rate | 0.23 |
Stock Price Statistics
The stock price has increased by 46.63% in the last 52 weeks. The beta is 0.56, so United Therapeutics Corporation's price volatility has been higher than the market average.
| Beta | 0.56 |
| 52-Week Price Change | 46.63% |
| 50-Day Moving Average | 369.26 |
| 200-Day Moving Average | 312.32 |
| Relative Strength Index (RSI) | 41.71 |
| Average Volume (20 Days) | 332.96K |
Income Statement
In the last 12 months, United Therapeutics Corporation had revenue of $2.33B and earned $984.80M in profits. Earnings per share was $21.04.
| Revenue | 2.33B |
| Gross Profit | 2.07B |
| Operating Income | 1.18B |
| Net Income | 984.80M |
| EBITDA | 1.39B |
| EBIT | 1.18B |
| Earnings Per Share (EPS) | 21.04 |
Balance Sheet
The company has $1.21B in cash and $700.00M in debt, giving a net cash position of $507.70M.
| Cash & Cash Equivalents | 1.21B |
| Total Debt | 700.00M |
| Net Cash | 507.70M |
| Retained Earnings | 6.03B |
| Total Assets | 7.12B |
| Working Capital | 3.13B |
Cash Flow
In the last 12 months, operating cash flow was $978.00M and capital expenditures -$230.40M, giving a free cash flow of $747.60M.
| Operating Cash Flow | 978.00M |
| Capital Expenditures | -230.40M |
| Free Cash Flow | 747.60M |
| FCF Per Share | 15.97 |
Margins
Gross margin is 88.94%, with operating and profit margins of 50.91% and 42.31%.
| Gross Margin | 88.94% |
| Operating Margin | 50.91% |
| Pretax Margin | 54.75% |
| Profit Margin | 42.31% |
| EBITDA Margin | 59.58% |
| EBIT Margin | 50.91% |
| FCF Margin | 32.12% |
Dividends & Yields
UTHR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.82% |
| FCF Yield | 4.63% |
Analyst Forecast
The average price target for UTHR is $344, which is -4.8% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $344 |
| Price Target Difference | -4.8% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
Stock Splits
The last stock split was on Sep 23, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 23, 2009 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 12.42 |
| Piotroski F-Score | 8 |